Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a ...

Retrieved on: 2025-09-26 17:47:38

Tags for this article:

Click the tags to see associated articles and topics

Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a .... View article details on hiswai:

Excerpt

Lund, Sweden, 26 September, 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today.

Article found on: news.cision.com